Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.57 |
| ▸ | KRAS | P01116 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29803176 | 1.00 | ABCG2 (0.84) | ABCG2ABCB1NR1H4ALDH1A1LMNA | |
| SCHEMBL499524 | 0.92 | ABCG2 (1.00) | ABCG2ABCB1NR1H4ALDH1A1LMNA | |
| SCHEMBL29803073 | 0.92 | ABCG2 (1.00) | ABCG2ABCB1NR1H4ALDH1A1LMNA | |
| SCHEMBL14922407 | 0.92 | ABCG2 (1.00) | ABCG2ABCB1NR1H4ALDH1A1LMNA | |
| SCHEMBL21643410 | 0.84 | ABCG2 (0.84) | ABCG2ABCB1NR1H4ALDH1A1LMNA | |
| SCHEMBL29803395 | 0.84 | ABCG2 (0.84) | ABCG2ABCB1NR1H4ALDH1A1LMNA | |
| SCHEMBL21643411 | 0.82 | ABCB1 (0.61) | ABCG2ABCB1ALDH1A1LMNAMAPT | |
| SCHEMBL21643408 | 0.82 | ABCB1 (0.61) | ABCG2ABCB1ALDH1A1LMNAMAPT | |
| SCHEMBL21643382 | 0.81 | DPP4 (0.66) | ABCG2NR1H4 | |
| SCHEMBL29803208 | 0.81 | DPP4 (0.66) | ABCG2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220363692-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| EP-4037702-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114746103-A | Rapafucin derivative compounds and methods of use thereof | 约翰霍普金斯大学 | 2022-07-12 | — | — | CN | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ABCG2 2061/4885ABCB1 2556/4885NR1H4 1419/4885 |
| US-20220363692-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ABCG2 2061/4885ABCB1 2556/4885NR1H4 1419/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ABCG2 2061/4885ABCB1 2556/4885NR1H4 1419/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ABCG2 2061/4885ABCB1 2556/4885NR1H4 1419/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ABCG2 2061/4885ABCB1 2556/4885NR1H4 1419/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ABCG2 2061/4885ABCB1 2556/4885NR1H4 1419/4885 |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, CHP1, FKBP8 | ABCG2 1242/4885ABCB1 1083/4885NR1H4 275/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | ABCG2 1922/4885ABCB1 2589/4885NR1H4 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.